Evidence map›Paper›PMID 40053523›Full record

ArticlePLoS computational biology2025

iSoMAs: Finding isoform expression and somatic mutation associations in human cancers.

Hua Tan, Valer Gotea, Sushil K Jaiswal, Nancy E Seidel, David O Holland, Kevin Fedkenheuer, Abdel G Elkahloun, Sara R Bang-Christensen, Laura Elnitski

Abstract read
In one paragraph

Article in PLoS computational biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hua TanTranslational and Functional Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America.ORCID 0000-0003-4090-113X
Valer GoteaTranslational and Functional Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America.ORCID 0000-0001-7857-3309
Sushil K JaiswalTranslational and Functional Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America.ORCID 0000-0001-7854-6255
Nancy E SeidelTranslational and Functional Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
David O HollandTranslational and Functional Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Kevin FedkenheuerTranslational and Functional Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Abdel G ElkahlounMicroarrays and Single-Cell Genomics Core, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Sara R Bang-ChristensenTranslational and Functional Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Laura ElnitskiTranslational and Functional Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America.ORCID 0000-0003-1065-019X

Funding

Regulatory and epigenetic landscapes reveal biological processes, disease mechanisms and diagnostic markersZIAHG200323 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI ELNITSKI, LAURA L · 2009 to 2025
$27.6M
Carlsberg FoundationNHGRI NIH HHS INTRAMURALNIH HHS ZIAHG200323
6 · The paper itself

Abstract

Aberrant alternative splicing, prevalent in cancer, impacts various cancer hallmarks involving proliferation, angiogenesis, and invasion. Splicing disruption often results from somatic point mutations rewiring functional pathways to support cancer cell survival. We introduce iSoMAs (iSoform expression and somatic Mutation Association), an efficient computational pipeline leveraging principal component analysis technique, to explore how somatic mutations influence transcriptome-wide gene expression at the isoform level. Applying iSoMAs to 33 cancer types comprising 9,738 tumor samples in The Cancer Genome Atlas, we identified 908 somatically mutated genes significantly associated with altered isoform expression across three or more cancer types. Mutations linked to differential isoform expression occurred through both cis- and trans-acting mechanisms, involving well-known oncogenes/suppressor genes, RNA binding protein and splicing factor genes. With wet-lab experiments, we verified direct association between TP53 mutations and differential isoform expression in cell cycle genes. Additional iSoMAs genes have been validated in the literature with independent cohorts and/or methods. Despite the complexity of cancer, iSoMAs attains computational efficiency via dimension reduction strategy and reveals critical associations between regulatory factors and transcriptional landscapes.

Indexed as

Alternative SplicingMutationNeoplasmsComputational BiologyGene Expression ProfilingGene Expression Regulation, NeoplasticHumansPrincipal Component AnalysisProtein IsoformsTranscriptomeProtein Isoforms

Identifiers

PMID40053523
PMCPMC12052144

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.